Menu ×


Growth Hormone Deficiency Market Segmentation By Application (Growth Hormone Deficiency, Prader-Willi Syndrome, Turner Syndrome, Idiopathic Short Stature, Small For Gestational Age, and Others); By Route of Administration (Intravenous, Intramuscular, Subcutaneous, and Oral); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Clinics, and E-Commerce Websites) - Global Demand Analysis & Opportunity Outlook 2028

  • Text Size:

Extensive insights into the Growth of Growth Hormone Deficiency Market amidst COVID-19

Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.

Request Insights


  • October 21, 2019: OPKO Health Inc. and Pfizer Inc. declared that its positive phase 3 top-line results for  Somatrogon, a growth hormone. The top-line results from the study validated that treatment with Somatrogon dosed once in a week in pre-pubertal children with growth hormone deficiency was non-inferior to Somatropin dosed once, daily.

  • November 2019: Novartis signed a contract to procure The Medicines Company, a biopharmaceutical company. The procurement would bring inclisiran, a potentially transformational medicine for cholesterol-lowering therapy, that reimagines the treatment of atherosclerotic heart disease and familial hypercholesterolemia along with expanding the biopharmaceuticals business of the company.

  • June 12, 2019: Ipsen prolonged its contract for another 15 years with Debiopharm for the renewal of its Decapeptyl, a regular gonadotropin-releasing hormone (GnRH). Under this partnership, the companies intended to develop, manufacture, and issue Decapeptyl across Europe and certain Asian and African markets.

Growth Hormone Deficiency Market Overview

Growth Hormone stimulates the growth of all essential tissues of the human body, including bone. Growth hormone deficiency (GHD) is a disorder that is caused due to the lack of growth hormones and is caused when the pituitary gland doesn’t produce enough concentration of human growth hormone also referred to as somatotropin. Several genetic disorders, such as Prader-Willi syndrome and Turner syndrome, might also be the reason for growth hormone deficiency in humans, leading to late puberty and shorter-than-average height. The condition can follow at any stage in a person’s life and treatments comprise growth hormone injections to stimulate growth.

Market Size and Forecast

The growth hormone deficiency market is expected to observe an attainable high CAGR during the forecast period, i.e., 2020-2028. The market is segmented by application, route of administration, distribution channel, and region. Among product applications, the Turner syndrome segment is expected to dominate the market on account of a surge in its incidence across the globe and better awareness of Turner syndrome in the medical community. Turner syndrome is a chromosomal abnormality in females, characterized by the partial or complete loss of one of the X chromosomes. As the syndrome is associated with many complications related to heart, hearing loss, autoimmune disorders, mental health issues, infertility, and pregnancy complications, the demand for treatment concerning growth hormones is growing.

Non-profit establishments such as Turner Syndrome Support Society (U.K.), Turner Syndrome Society of the United States, and Turner Syndrome Foundation celebrate “Turner Syndrome Awareness Month” every year and spread awareness about the condition via nationwide campaigns which were affected this year owing to COVID-19.

Growth Drivers

Increase in the prevalence of serious chronic diseases

Chronic diseases such as growth retardation, pituitary dysfunctions, accompanied by changing lifestyle, the prevalence of other genetic disorders, incidence of GHD in adults, and surge in compliance for growth hormone creations are the key factors that are driving the growth of the global growth hormone deficiency market. CLICK TO DOWNLOAD SAMPLE REPORT

Furthermore, initiatives taken by numerous government and private organizations to spread alertness about growth hormone deficiencies,  rise in disposable income, a surge in healthcare facilities in developing nations, and awareness for human growth hormone treatment are estimated to drive the market growth during the forecast period.


Unfavorable effects of growth hormones on the human body

Side effects of growth hormones such as muscle pain, joint pain, and fluid retention might surface are the growth hindrances for the growth hormone deficiency market.

Furthermore, stringent government regulations and high cost involved in the treatments using these growth hormones might also contribute as growth constraints for the overall growth hormone deficiency market.

Market Segmentation

Our in-depth analysis of the growth hormone deficiency market includes the following segments:

By Application

  • Growth Hormone (GH) Deficiency
    • Adult GH Deficiency
    • Pediatric GH Deficiency
  • Turner Syndrome
  • Idiopathic Short Stature
  • Prader-Willi Syndrome
  • Small for Gestational Age
  • Other

By Route Of Administration

  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Oral

 By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Clinics
  • E-Commerce Websites

By Region

Geographically, the growth hormone deficiency market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.

North America is projected to hold the largest market share in the forecast period. The dominance is attributed towards the factors such as high healthcare expenditure, and amplified intake of human growth hormone therapies in this region in order to cure different syndromes such as Turner syndrome. Further, the ease of availability of artificial growth hormones, rise in research and development concerning human growth hormone, and the availability of reimbursements are further contributing towards the regional growth.

The European region is anticipated to hold the second-largest market share in the growth hormone deficiency market. The growth in this region is attributed to the rising incidences of growth hormone deficiencies, increasing inclination towards growth hormones for the treatment of Idiopathic Short Stature (ISS), and rising government spending for the healthcare facilities in the region.

Asia-Pacific is estimated to grow at the fastest rate during the forecast period. Factors such as a rise in the incidence of growth hormone deficiency disorders, upsurge in healthcare expenditure, infiltration of leading players, growing population, and a rise in disposable income, are projected to propel the growth in the Asia-Pacific region.

The growth hormone deficiency market is further classified based on region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • the Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of the Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis.

Top Featured Companies Dominating The Market

Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved